Drug resistance in human neuroblastoma cell lines correlates with clinical therapy

European Journal of Cancer

Volumn 33, Issue 12, 1997, Pages 2002-2006

  Keshelava, N ^a   Seeger, R C ^a,b   Reynolds, C P ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Chemotherapeutic agents; Drug resistance; Neuroblastoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; MELPHALAN;

ADRENERGIC SYSTEM; BONE MARROW TRANSPLANTATION; CONFERENCE PAPER; CYTOTOXICITY; GENE MUTATION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; PHENOTYPE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; HUMANS; MELPHALAN; NEUROBLASTOMA; TUMOR CELLS, CULTURED;

EID: 0031417657     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00213-X     Document Type: Conference Paper

References (30)

1. Hartmann O., Pinckerton C. R., Philip T., Zucker J. M., Breatnach F. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol. 6:1988;44-50.
2. Seeger RC, Villablanca JG, Matthay KK, et al. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 1991, 66, 527-533.
3. LaQuaglia M. P., Kopp E. B., Spengler B. A., Meyers M. B., Beidler J. L. Multidrug resistance in human neuroblastoma cells. J Ped Surg. 26:(9):1991;1107-1112.
4. Goldstein LJ, Fojo AT, Ueda K, et al. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J Clin Oncol 1990, 8, 128-136.
5. Norris M. D., Bordow S. B., Marshall G. M. Expression of the gene for multidrug-resistance associated protein and outcome in patients with neuroblastoma. N Engl J Med. 334:1996;231-238.
6. Kushner B. H., Vogel R., Hajdu S. I., Helson L. Metastatic neuroblastoma and testicular involvement. Cancer. 56:1985;1730-1732.
7. Kennedy K. A. Hypoxic cells as specific targets for chemotherapy. Anticancer Drug Des. 2:1987;181-194.
8. Sartorelli A. C. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res. 48:1988;775-778.
9. Hayes F. A., Green A. A., Mauer A. M. Correlation of cell kinetics and clinical response to chemotherapy in disseminated neuroblastoma. Cancer Res. 37:1977;3766-3770.
10. Rosen N., Reynolds C. P., Thiele C. J., Biedler J. L., Israel M. A. Increased N-myc expression following progressive growth of human neuroblastoma. Cancer Res. 46:1986;4139-4142.
11. Reynolds CP, Biedler JL, Spengler BA, et al. Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 1986, 76, 375-387.
12. Wada RK, Seeger RC, Brodeur GM, et al. Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer 1993, 72, 3346-3354.
13. Proffitt R. T., Tran J. V., Reynolds P. C. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry. 24:1996;204-213.
14. Frgala T., Proffitt R. T., Reynolds C. P. A novel 96-well plate cytotoxicity assay based on fluorescence digital imaging microscopy. Proc Am Assoc Cancer Res. 36:1995;303.
15. Chou J, Chou T CH. Multiple drug-effect analysis (program B). In Chou J, Chou T CH, eds. Dose-effect analysis with microcomputers, New York, Memorial Sloan-Kettering Cancer Center, 1987, 19-64.
16. Sabbagh R., Leclerc J. M., Sunderland M., Theoret Y. Chronopharmacokinetic of a 48-hr continuous infusion of doxorubicin to children with acute lymphoblastic leukemia. Proc Am Assoc Cancer Res. 34:1993;198.
17. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989, 7, 1333-1340.
18. Komiyama S, Matsui K, Kudoh S, et al. Establishment of tumor cell lines from a patient with head and neck cancer and their different sensitivities to anti-cancer agents. Cancer 1989, 63, 675-681.
19. Ma DDF, Davey RA, Harman DH. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet, 1987, 135-137.
20. Schneider E., Cowan K. H., Bader H. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood. 85:1995;186-193.
21. Hamaguchi K., Godwin A. K., Yakushiji M., et al. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 53:1993;5225-5232.
22. Sugimoto Y., Roninson I. B., Tsuruo T. Decreased expression of the amplified mdr1 gene in revertants of multidrug-resistant human myelogenous leukemia K562 occurs without loss of amplified DNA. Mol Cell Biol. 7:1987;4549-4552.
23. Zalcberg J. R., Hu X. F., Slater A., et al. Rapid but differential upregulation of MDR1 expression by anthracyclines in a classical drug resistant cell line. Anticancer Drugs. 5:(Suppl. 1):1994;6-7.
24. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47, 381-389.
25. Ueda K., Cardarelli C., Gottesman M. M., Pastan I. Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 84:1987;3004-3008.
26. Grant C. E., Valdimarsson G., Hipfner D. R., Almquist K. C., Cole S. P., Deeley R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54:1994;357-361.
27. Lai G.-M., Ozols R. F., Smyth J. F., Young R. C., Hamilton T. C. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol. 37:1988;4597-4600.
28. Parker R. J., Eastman A., Bostick-Bruton F., Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest. 87:1991;772-777.
29. Loh S. Y., Mistry P., Kelland L. R., Abel G., Harrap K. R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum(II) and (IV) ammine/amine complexes. Br J Cancer. 66:1992;1109-1115.
30. Yao K.-S., Godwin A. K., Johnson S. W., et al. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res. 55:1995;4367-4374.